Clinical Trial Update: Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on a Genzyme-sponsored therapy for moderate to severe Crohn's disease reporting efficacy and safety data; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Genzyme investigational product

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED